As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

Theratechnologies said Thursday that patients will encounter a shortage of Egrifta SV--its prescription medicine that reduces excess belly fat in adults with HIV and lipodystrophy--in mid-January. The ...

A once-daily dose of ivarmacitinib reduced disease activity and improved function among patients with rheumatoid arthritis ...

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

High serum CXCL13 levels are predictive of treatment failure with first-line MTX among patients with early RA.

Nurse-led care effectively reduces disease activity and improves self-efficacy in patients with rheumatoid arthritis, ...

A recent study by Maheen Asif and team unveiled great outcome of abatacept in delaying the progression of rheumatoid ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

In recent years treatment with powerful biologic and targeted synthetic therapies has changed the landscape for arthritis, but currently finding the right treatment for each person is a matter of ...